Navigation Links
Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
Date:4/23/2009

fizer") is completed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 25, 2009, upon the completion of the merger, each share of Common Stock will be converted into the right to receive $33.00 in cash plus 0.985 of a share of Pfizer common stock, subject to adjustment in limited circumstances. On April 22, 2009, the closing price of Pfizer's common stock on the NYSE was $13.04 per share.

Considering the number of shares of Common Stock into which each share of Convertible Preferred Stock is convertible as compared to the redemption price of $60.08 for each share of Convertible Preferred Stock, Wyeth expects the holders of all or substantially all of the Convertible Preferred Stock will elect to convert their shares into Common Stock prior to the Redemption Date.

Wyeth is redeeming the Convertible Preferred Stock pursuant to a request from Pfizer made in accordance with the terms and conditions of the Merger Agreement, although the redemption is not in any way contingent upon the closing of the merger. A Notice of Redemption, which will describe the redemption procedures as well as the fact that holders may elect to convert their Convertible Preferred Stock into Common Stock prior to the Redemption Date, will be sent no later than June 15, 2009 by Wyeth to all record owners of Convertible Preferred Stock. Additional information related to the procedures for redemption, including copies of the Notice of Redemption following its distribution, may be obtained from BNY Mellon Shareowner Services by calling (800) 777-3674.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Co
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Wyeth Declares Common and Preferred Stock Dividends
2. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
3. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
4. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
5. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
6. Wyeth Declares Preferred Stock Dividend
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
9. Wyeth Announces Increase in Common Stock Dividend
10. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
11. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  David Hardison, Ph.D., vice president of health ... been elected chairman of the board for the ... to establish common protocols around the use of ... electronic health records. Hardison will ... organizations across the research and health care arena ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... DST Health Solutions, LLC, today launched new versions ... Advance, PowerMHC, PowerMHS and PowerSTEPP. The platforms now support ... & Medicaid Services (CMS). This change—from Version 4010/4010A to ... effective Jan. 1, 2012, as designated by CMS. ...
... I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
... 2010 Cardium Therapeutics (NYSE Amex: CXM ... and Chief Executive Officer will present at the LifeTech ... at 2:00 p.m. Eastern.  The conference will take place ... presentation will not be webcast, investors can access the ...
Cached Biology Technology:HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 2HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 2YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 4YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 5YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 6YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 7YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 8YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 9YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 10YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 11YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 12Cardium to Present at the LifeTech Capital Miami Medical Investors Conference 2
(Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
(Date:7/28/2014)... to map social connections in prairie dogs have ... light on prairie dog communities that may help ... future conservation efforts. The work was done by ... National Evolutionary Synthesis Center (NESCent). , "Prairie dogs ... plague," says Dr. Jennifer Verdolin, lead author of ...
(Date:7/27/2014)... species of mayfly in the southern Western Ghats, a mountain ... is the first time that any mayfly belonging to the ... , The new species, called Labiobaetis soldani , "is ... contribution to the understanding of the Ephemeroptera of Palaearctic and ... describes the new mayfly in the Journal of Insect ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Social network research may boost prairie dog conservation efforts 2
... combination of the biology of marine mammals, mechanical vibrations ... scientists to better understand the potential harmful effects of ... An international team of researchers from UC ... Zoo in Sweden has developed an approach that integrates ...
... 31, 2010 − A York University doctoral student who discovered ... lab one morning has completed a study that examines 84 ... including the one Jason Gibbs found in downtown Toronto ... identified or described before. Gibbs, expansive study will help ...
... brains, mouth bacteria behaving badly and the hundreds of ... some of the highlights at the Society for General ... annual event takes place on 6-9 September at the ... experts will present cutting-edge scientific research covering a wide ...
Cached Biology News:Researchers develop simulation to better understand the effects of sound on marine life 2Researchers develop simulation to better understand the effects of sound on marine life 3York U researcher finds new bee in downtown Toronto 2
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... 220-240 V, uses floating pin printing technology ... and other biomolecules onto a variety of ... generate high-density arrays with greater than 80,000 ... 57,000 spots per membrane with a capacity ...
... systems are high-precision microarrayers capable of ... samples. VersArray ChipWriter Pro systems set ... and reproducibility to deliver unparalleled quality ... Their modular component design and flexible ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: